Date: 2014-12-10
Type of information: Nomination
Compound: member of the supervisory board
Company: Noxxon (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 10, 2014, Noxxon Pharma has appointed Don deBethizy to the Company’s Supervisory Board. In his last position as President and Chief Executive Officer of Santaris Pharma A/S, Don deBethizy initiated and managed the successful acquisition of the company by Roche. Previously, he was Executive Chairman of Danish bio-venture firm, Contera Pharma and oversaw its sale to Korean Bukwang Pharmaceutical. From 1997 to 2012, Dr. deBethizy was co-founder and CEO of Targacept. He is currently on the Board of Directors of Newron Pharmaceuticals. Don deBethizy holds a BS degree in Biology from the University of Maryland and received a Ph.D. in Toxicology from Utah State University. He will join the current Supervisory Board of Noxxon which consists of seven industry and investor representatives.
Financial terms:
Latest news:
Is general: Yes
